Good Physician Adherence to Guideline-Directed Medical Therapy Associated with Lower Patient Mortality and Hospitalisation Rates Across The World by Rohman, Mohammad Saifur
Good Physician Adherence to Guideline-Directed Medical Therapy 
Associated with Lower Patient Mortality and Hospitalisation Rates 
Across The World
A R T I C L E I N F O A B S T R A C T
Heart Science Journal
Contents list available at www.heartscience.ub.ac.id
Heart Sci J 2020; 1(1): 1-3
Journal Homepage : www.heartscience.ub.ac.id
While the guidelines for the managements of heart diseases have been well-developed and updated periodically, 
they do not guarantee to reduce the number of heart disease morbidity and mortality. Since the holistic approach 
is not carefully applied, this morbidity rate may not be significantly reduced. The holistic approach to managing 
heart disease has broad aspects, but the most important aspect is regarding physician adherence to Guideline-Di-
rected Medical Therapy (GDMT). This paper aimed to discuss the physician adherence to GDMT, and its role in 
reducing morbidity and in-hospitalization in heart disease patients. Several large scale studies have revealed that 
good adherence to heart failure treatment guidelines among physicians improved not only quality of life but also 
resulted in a better prognosis. On other hands, because the main target of physicians adherence to GDMT is to 
achieve maximally tolerated dose, it is also important that the understanding when and how to add, switch, and 
titrate all therapies to maximally tolerated doses and ideally target doses is important to reduce the morbidity and 
mortality of heart disease patients. However, in some points, this principle might not be applied properly due to 
several limitations. In this case, physicians may have to consider the balance between patients preferences, 
healthcare resources, and the risk of adverse outcomes. In conclusion,  it should be noted that physician 
adherence to GDMT has an important role to reduce morbidity and mortality of heart disease patients.
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 The incidence of heart failure (HF) is steadily increasing with 
an estimated 26 million people afflicted world-wide. This increase can 
be attributed to several factors, including prompt and improved 
treatment for acute myocardial infarction, an increasing prevalence of 
hypertension, diabetes mellitus, and aging population.1,2 HF manage-
ment consumes significant health care resources, inflicts significant 
morbidity and mortality, and greatly impacts quality of life. Annually, 
HF is the primary reason for 12 million to 15 million office visits.3 
Hospitalization due to heart failure as a primary diagnosis is reported 
in over 1 million patients yearly as a first diagnosis with an additional 
3 million hospitalizations as a contributing diagnosis.4 Several studies 
suggested HF readmission rate at 30 days was 4.9 % while 90 day 
rehospitalisation rate was approximately 25%. Data from 
OPTIMIZE-HF, Euro-Heart Failure Survey II and other studies reported 
in-hospital mortality  was vary from 3% to 9%. One year Mortality rates 
ranged across the different regions from 21.6 % to 36.5 %.5 
 
 Significant advances have been made in the pharmacologic 
treatment of HF in recent decades. The benefits of β-blockers, angioten-
sin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, 
aldosterone antagonists, and isosorbide dinitrate or hydralazine have 
been supported by a large number of randomized clinical trials (RCT) 
showing improvements of symptoms, reduce burden of hospitalization, 
and/or provide survival benefit. Cardiac societies have published 
updated HF guidelines regularly, according to the recent RCTs.6   
 Previous studies also suggested that good adherence to HF 
treatment guidelines among physicians improved not only quality of 
life but also resulted in a better prognosis.7 Therefore, understanding 
when and how to add, switch, and titrate all therapies to maximally 
tolerated doses and ideally target doses is important. To achieve the 
maximal benefits of Guideline-directed medical therapy (GDMT) in 
patients with HF therapies must be initiated and titrated to maximally
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Note; Digoxin remains indicated for HFrEF, but there are no contemporary data 
to warrant additional comment in this document. The reader is referred to 
already available guideline statements (2). *Isosorbide mononitrate is not 
recommended by the ACC/AHA/HFSA guideline. † The ACC/AHA/HFSA 
guideline considers either the fixed dose combination or the separate combina-
tion of isosorbide dinitrate and hydralazine as appropriate guideline directed 
therapy for HF. ACEI = angiotensin-converting enzyme inhibitor; ARNI = 
angiotensin receptor neprilysin inhibitor; ARB = angiotensin receptor blocker; 
bpm = beats per minute; HF = heart failure; HFrEF = heart failure with 
reduced ejection fraction. ( Source: Adapted from Yancy CW et al., 2017)
 Achieving target or maximally tolerated doses of GDMT is 
the goal. β-blocker doses should be adjusted every 2 weeks in a patient 
with no evidence of decompensated HF and no contraindications to 
higher doses. Longer time periods may be needed for frail patients or 
those with marginal hemodynamics, whereas more rapid titration may 
be reasonable in clinically stable patients without hypotension. Follow-
ing adjustment, patients should be cautioned that there may be a 
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1.
Starting dose Target dose
Beta Blockers
Bisoprolol 1.25 mg once daily 10 mg once daily
Carvedilol 3.125 mg twice daily 25 mg twice daily for
weight <85 kg and
50 mg twice daily for
weight >
Metoprolol succinate 12.5–25 mg/d 200 mg daily
ARNI
Sacubitril/valsartan 24/26 mg–49/51 mg
twice daily
97/103 mg twice daily
ACEI
Captopril 6.25 mg 3 daily 50 mg 3x daily
Enalapril 2.5 mg twice daily 10 –20 mg twice daily
Lisinopril 2.5–5 mg daily 20– 40 mg daily
Ramipril 1.25 mg daily 10 mg daily
ARB
Candesartan 4 –8 mg daily 32 mg daily
Losartan 25–50 mg daily 150 mg daily
Valsartan 40 mg twice daily 160 mg twice daily
Aldosterone antagonists
Eplerenone 25 mg daily 50 mg daily
Spironolactone 12.5–25 mg daily 25–50 mg daily
Vasodilators
Hydralazine 25 mg 3 daily 75 mg 3 daily
Isosorbide dinitrate* 20 mg 3 daily 40 mg 3 daily
Fixed-dose
combination
isosorbide dinitrate/
hydralazine†
20 mg/37.5 mg
(one tab)
3 daily
2 tabs 3 daily
Ivabradine
Ivabradine 2.5 –5 mg twice
daily
Titrate to heart
rate 50 – 60 bpm.
Maximum dose
7.5 mg twice daily
85 kg
transient worsening of HF symptoms such as dyspnea, fatigue, or 
dizziness. ACEI and ARB may be titrated similarly to beta blockers with 
monitoring of renal function, potassium, and blood pressure; more 
rapid titration is also reasonable in clinically stable patients. In the 
absence of hypotension, electrolyte/renal instability, or angioedema on 
an ACEI or ARB, it is reasonable to change to ARNI.8  
 In some instances, it may not be possible to titrate GDMT to 
the target doses achieved in clinical trials. Patients in clinical practice 
may differ substantially from those enrolled in the trials; such differenc-
es may limit the ability to titrate therapies. For example, patients in 
clinical practice are typically older, may experience more side effects, 
and are likely to have more comorbidities that will limit titration. Social 
or economic barriers to care may also undermine ability to achieve 
GDMT.8  
 The optimal time-point for discharging hospitalised HF 
patients may be difficult to determine due to the need to balance 
patient preferences, healthcare resources and the risk of adverse 
outcomes. Indeed, the risk of death is high during hospitalisation for HF 
but is even higher during the immediate post-discharge period, which 
usually lasts 2–3 months and is known as the vulnerable phase.9 
Persistent subclinical congestion may contribute to the high rates of 
death and readmission observed after hospital discharge.10 Indeed, 
despite a global improvement in symptoms during hospital stay, a 
relevant proportion of patients still display markedly elevated 
natriuretic peptides at discharge. Based on these data, titration of 
decongestive therapy based only on symptoms and signs may be insuffi-
cient and should include additional parameters, such as biomarkers 
and/or echocardiography.11,12 Waranugraha Y. et all. reported the 
benefit of measuring ePCWP using echocardiography, similar to 
NT-proBNP sensitivity to assess hemodynamic congestion which 
present in 48% HF patients without appearance clinical congestion. 
Among 50% of hemodynamic congestion patients readmitted to 
hospital within 30 days.13
 Underutilisation of heart failure therapies such as beta- 
blockers, renin–angiotensin system (RAS) inhibitors and mineralocorti-
coid receptor antagonists was prevalent and showed a 40–50 % relative 
risk reduction in 90-day mortality.14,15 Additional 25–50 % relative risk 
reduction was shown after beta-blocker and RAS inhibitor combination 
therapy at hospital discharge compared to either treatment alone. The 
early benefits were present in both reduced and preserved ejection 
fraction and persisted at 1-year follow up.15 Utomo YB. et all. has 
reported in this issue the role of GDMT during hospitalisation resulted 
in lower in hospital mortality. They also mentioned only 17% of HF 
patients receiving optimal angiotensin converting enzyme inhibitors 
(ACEi) suggesting low adherence of physician  to GDMT in the study.
 QUALIFY (Quality of Adherence to guideline recommenda-
tions for LIFe-saving treatment in heart failure surveY) has demonstrat-
ed also that good physician adherence to guideline recommendations 
for key heart failure medication (angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers, beta blockers, mineralocorti-
coid receptor antagonists and ivabradine) is associated with lower 
patient mortality and hospitalisation rates across the world. It under-
lines the importance of physicians’ adherence to recommended drugs 
and drug dosages in improving clinical outcomes for patients with heart 
failure.7 
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tolerated doses (See table1). Doses of GDMT higher than those studied 
in randomized clinical trials, even if tolerated, are not known to provide 
incremental benefits and are generally not recommended.8 
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